Many pharma companies have breakthrough AI results in isolated functions, or "pockets of excellence." However, the ultimate competitive advantage will go to the company that first connects these disparate successes into a single, integrated, enterprise-wide AI capability, thereby creating compounded value across the organization.
Related Insights
A significant implementation roadblock is the ownership battle between IT and business functions. IT wants to control infrastructure and moves slowly, taking years. In response, business units run their own unsanctioned initiatives to move quickly, leading to a disconnected and unscalable approach to AI.
Companies struggle with AI not because of the models, but because their data is siloed. Adopting an 'integration-first' mindset is crucial for creating the unified data foundation AI requires.
Companies run numerous disconnected AI pilots in R&D, commercial, and other silos, each with its own metrics. This fragmented approach prevents enterprise-wide impact and disconnects AI investment from C-suite goals like share price or revenue growth. The core problem is strategic, not technical.
Many firms are stuck in "pilot purgatory," launching numerous small, siloed AI tests. While individually successful, these experiments fail to integrate into the broader business system, creating an illusion of progress without delivering strategic, enterprise-level value.
Many pharma companies allow various departments to run numerous, disconnected AI pilots without a central strategy. This lack of strategic alignment means most pilots fail to move beyond the proof-of-concept stage, with 85% yielding no measurable return on investment.
The true enterprise value of AI lies not in consuming third-party models, but in building internal capabilities to diffuse intelligence throughout the organization. This means creating proprietary "AI factories" rather than just using external tools and admiring others' success.
A traditional IT investment ROI model misses the true value of AI in pharma. A proper methodology must account for operational efficiencies (e.g., time saved in clinical trials, where each day costs millions) and intangible benefits like improved data quality, competitive advantage, and institutional learning.
The business race isn't about humans versus AI, but about your company versus competitors who integrate AI more quickly and effectively. The sustainable competitive advantage comes from shrinking the cycle time from a new AI breakthrough to its implementation within your business processes and culture.
McKinsey finds over half the challenge in leveraging AI is organizational, not technical. To see enterprise-level value, companies must flatten hierarchies, break down departmental silos, and redesign workflows, a process that is proving harder and longer than leaders expect.
Many companies focus on AI models first, only to hit a wall. An "integration-first" approach is a strategic imperative. Connecting disparate systems *before* building agents ensures they have the necessary data to be effective, avoiding the "garbage in, garbage out" trap at a foundational level.
